Charles River Laboratories

Healthcare · Diagnostics & Research

294.40$ +6.2% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Income Statement

Charles River Laboratories (CRL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 1,004 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement CRL
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	426	467	446	469	464	478	494	585	585	602	605	658	668	691	707	683	743	791	825	915	896	905	914	973	989	1,100	1,029	1,060	1,027	1,013	1,012	1,026	1,010	1,003	984	1,032	1,005	994	996	1,004	3,999
Cost of Revenue	269	287	274	284	287	311	313	369	369	375	393	419	422	429	455	450	454	491	516	573	559	558	577	616	619	701	652	661	665	649	667	672	661	718	666	675	666	686	717	641	2,710
Gross Profit	156	180	171	185	177	168	181	216	216	226	212	238	246	262	252	232	289	300	308	342	337	347	337	357	370	399	378	399	362	364	345	354	349	284	318	357	339	308	279	363	1,289
Research & Development	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Selling, General & Administrative	83	98	90	94	93	91	103	121	108	105	117	123	126	120	124	123	128	154	156	168	149	144	150	132	184	200	175	200	176	197	186	170	199	196	178	192	178	188	159	229	754
Total Operating Expenses	97	111	102	104	103	105	114	139	132	124	142	158	153	154	158	155	157	171	185	204	181	174	188	169	219	235	210	234	210	231	219	202	232	452	243	257	205	188	159	243	796
Operating Income	59	69	70	82	74	63	68	77	84	102	70	80	93	109	94	77	133	129	124	138	156	173	149	187	151	164	168	165	152	133	126	152	117	-168	75	100	134	120	120	120	494
Interest Expense	7.1	7.5	7.0	7.4	7.7	7.7	11	19	17	17	10.0	21	5.7	24	15	19	19	33	30	16	16	12	9.4	3.7	11	35	34	35	34	34	35	33	30	28	28	30	25	24	27	30	106
Pre-Tax Income	53	64	78	77	73	69	63	70	73	75	66	59	73	106	55	84	135	172	66	127	123	164	111	144	123	245	131	129	113	209	99	120	91	-217	36	71	87	-294	-30	53	-184
Income Tax Expense	16	18	31	22	20	98	9.8	17	12	15	11	15	-0.3	25	4.6	16	33	28	2.4	38	18	24	16	33	25	56	27	29	25	20	25	25	21	-3.0	10	19	32	-18	-15	54	53
Net Income	38	45	47	54	52	-30	53	54	60	60	55	44	73	80	51	67	103	143	62	88	103	138	93	109	96	187	103	97	87	187	67	90	69	-216	25	52	54	-277	-15	-1.5	-238
EBITDA	94	107	117	116	114	110	107	132	134	133	122	129	131	182	128	161	214	266	158	212	208	242	196	224	209	357	242	241	225	323	219	239	210	-86	184	221	198	-192	64	151	220

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings